FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Lightning Round: CVS Caremark, Devon Energy, Tyson Foods and More
- Lightning Round OT: Ford, NewAlliance Bancshares and More
- Why You Should Speculate on Stocks
- Next Week’s Top IPO
- Cramer: 5 Earnings Reports to Watch Next Week
- More Americans Lighting Up? Buy This Stock
- What Happened to Cypress Semi?
- Lightning Round: Raytheon, Salesforce.com, Pepsi and More
- Lightning Round OT: Apache, Brocade, Allergan and More
- Cramer Goes One-on-One With Costco CEO


It’s Speculation Friday on Mad Money, when Cramer recommends the riskiest, most dangerous stocks that also have the most potential upside. This week, the spotlight was on Tutogen Medical [TTG
Loading...
()
], a hugely speculative name but one with risk reward “too terrific to be ignored.”
Tutogen makes and sells materials used in soft tissue and bone repair. The stock is sitting about a dollar below its 52-week high of $12.27, which it reached after breaking out from the mid-$8 level on news of an expanded agreement with Zimmer Holdings [ZMH
Loading...
()
], Cramer said. Zimmer happens to represent about 80% of TTG’s sales and owns about 32% of of its shares. Cramer thinks it’s likely that TTG gets a takeover bid from Zimmer. It already did last year, but TTG rejected the offer because the price was too low. Cramer thinks Zimmer will try again and pay up this time.
Tutogen looks expensive, trading at 44 times next year’s numbers, but it has a 40 percent long-term growth rate and the company gets orders four months ahead of time for tissue, giving it good earnings visibility, Cramer said.
Cramer thinks it’s an eight up, one down situation for TTG. He could see the stock breaking through $20, but it’s hard to see it falling far below $10, especially considering a possible takeover by Zimmer.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?



